AC   CVCL_0485
AS   CVCL_6714
SY   PLC-PRF-5; PLC PRF 5; PLC/PRF5; PLCPRF5; PLC-8024; PLC8024; PLC; Alexander cells; Alexander; Primary Liver Carcinoma/Poliomyelitis Research Foundation/5
DR   BTO; BTO:0003492
DR   CLO; CLO_0008458
DR   CLO; CLO_0008459
DR   EFO; EFO_0006291
DR   MCCL; MCC:0000384
DR   CLDB; cl3914
DR   CLDB; cl3915
DR   CLDB; cl3916
DR   CLDB; cl5248
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ATCC; CRL-8024
DR   BCRC; 60223
DR   BCRJ; 0274
DR   BioGRID_ORCS_Cell_line; 484
DR   BioSample; SAMN03471130
DR   BioSample; SAMN03473236
DR   BioSample; SAMN10988112
DR   cancercelllines; CVCL_0485
DR   CCRID; 1101HUM-PUMC000674
DR   CCRID; 1102HUM-NIFDC00071
DR   CCRID; 3101HUMTCHu119
DR   CCRID; 4201HUM-CCTCC00644
DR   Cell_Model_Passport; SIDM01318
DR   CGH-DB; 9070-4
DR   ChEMBL-Cells; CHEMBL3308140
DR   ChEMBL-Targets; CHEMBL1075561
DR   CLS; 300315
DR   Cosmic; 721061
DR   Cosmic; 808505
DR   Cosmic; 871514
DR   Cosmic; 873402
DR   Cosmic; 925349
DR   Cosmic; 945155
DR   Cosmic; 948065
DR   Cosmic; 1019318
DR   Cosmic; 1351513
DR   Cosmic; 1518224
DR   Cosmic; 2023861
DR   Cosmic; 2162538
DR   Cosmic; 2321033
DR   Cosmic; 2674231
DR   Cosmic; 2773187
DR   DepMap; ACH-001318
DR   ECACC; 85061113
DR   EGA; EGAS00001000610
DR   GDSC; 925349
DR   GEO; GSM207051
DR   GEO; GSM565881
DR   GEO; GSM827153
DR   GEO; GSM886865
DR   GEO; GSM887520
DR   GEO; GSM887930
DR   GEO; GSM888602
DR   GEO; GSM936773
DR   GEO; GSM2551580
DR   GEO; GSM2551581
DR   IARC_TP53; 107
DR   IARC_TP53; 30016
DR   JCRB; IFO50069
DR   KCB; KCB 200785YJ
DR   KCLB; 28024
DR   LiGeA; CCLE_292
DR   NCBI_Iran; C145
DR   PharmacoDB; PLCPRF5_1274_2019
DR   Progenetix; CVCL_0485
DR   PubChem_Cell_line; CVCL_0485
DR   RCB; RCB1887
DR   TKG; TKG 0376
DR   TOKU-E; 2898
DR   Ubigene; YC-C125
DR   Wikidata; Q54947574
RX   DOI=10.1007/978-4-431-68349-0_4;
RX   DOI=10.11418/jtca1981.16.3_173;
RX   PubMed=63998;
RX   PubMed=184551;
RX   PubMed=187208;
RX   PubMed=1317878;
RX   PubMed=1661347;
RX   PubMed=2414854;
RX   PubMed=2439335;
RX   PubMed=2542205;
RX   PubMed=2992761;
RX   PubMed=2992762;
RX   PubMed=3023526;
RX   PubMed=6160110;
RX   PubMed=6225510;
RX   PubMed=6248960;
RX   PubMed=6268737;
RX   PubMed=6275024;
RX   PubMed=6288577;
RX   PubMed=6555060;
RX   PubMed=6889516;
RX   PubMed=7874267;
RX   PubMed=8050184;
RX   PubMed=8224613;
RX   PubMed=8389256;
RX   PubMed=8835345;
RX   PubMed=9023415;
RX   PubMed=9178645;
RX   PubMed=9290701;
RX   PubMed=9359923;
RX   PubMed=10523694;
RX   PubMed=11050057;
RX   PubMed=12029633;
RX   PubMed=15767549;
RX   PubMed=20069059;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=22460905;
RX   PubMed=23505090;
RX   PubMed=23887712;
RX   PubMed=25485619;
RX   PubMed=25574106;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=28196595;
RX   PubMed=29892436;
RX   PubMed=30894373;
RX   PubMed=31063779;
RX   PubMed=31068700;
RX   PubMed=31378681;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: JFCR45 cancer cell line panel.
CC   Part of: Liver Cancer Model Repository (LIMORE).
CC   Part of: MD Anderson Cell Lines Project.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8024.
CC   Population: African; Shangaan.
CC   Virology: Contains at least 7 copies of integrated hepatitis B virus (HBV) genomes. Secretes hepatitis virus B surface antigen (HBsAg).
CC   Virology: Susceptible to infection by adenovirus types 40 (Ad40) and 41 (Ad41) (PubMed=1317878).
CC   Doubling time: 35-40 hours (PubMed=63998); 20.05-28.76 hours (PubMed=31378681).
CC   HLA typing: A*33:02; B*42:01,53:01; C*04:01,17:01 (PubMed=9178645).
CC   HLA typing: A*03:01,33:03; B*42:02,53:01; C*04:01,17:01; DQB1*06:07,06:07; DRB1*11:73,11:73 (PubMed=26589293).
CC   HLA typing: A*03:01:01,09:03:01; B*42:02:01,53:01:01; C*04:01,04; DPB1*17,18:01; DQA1*01:03:01,04:01:02; DQB1*03:19:01,06:03:01; DRB1*08:04:01,13:01:01 (CLS=300315).
CC   Karyotypic information: Has lost chromosome Y.
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg112Gly (c.334C>G) (p.Pro126Arg, c.377C>G); ClinVar=VCV000233484; Zygosity=Homozygous (PubMed=31378681; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>T); ClinVar=VCV000012352; Zygosity=Homozygous (PubMed=8224613; PubMed=8389256; DepMap).
CC   Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Asn1651Ser (c.4952A>G); ClinVar=VCV000049335; Zygosity=Homozygous (DepMap).
CC   Transformant: NCBI_TaxID; 10407; Hepatitis B virus (HBV).
CC   Omics: Deep exome analysis.
CC   Omics: Genome sequenced.
CC   Omics: miRNA expression profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Secretome proteome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=95.79%; Native American=0%; East Asian, North=1.61%; East Asian, South=0%; South Asian=0%; European, North=0%; European, South=2.59% (PubMed=30894373).
CC   Caution: Often called PLC8024 in Chinese literature probably because of a concatenation between PLC/PRF/5 and ATCC-8024.
CC   Misspelling: PCL/PRF/5; Cosmic=873402.
CC   Discontinued: RCB; RCB1887; true.
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
ST   Source(s): ATCC; CCRID; CLS; ECACC; JCRB; KCLB; PubMed=25877200; PubMed=31378681
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D12S391: 15,20 (CCRID)
ST   D12S391: 20 (CLS; PubMed=25877200)
ST   D13S317: 11,12
ST   D16S539: 13
ST   D18S51: 17
ST   D19S433: 11,13
ST   D1S1656: 14
ST   D21S11: 30,33.2
ST   D2S1338: 19 (CLS; PubMed=25877200)
ST   D2S1338: 19,22 (CCRID)
ST   D2S441: 12,14
ST   D3S1358: 15
ST   D5S818: 12
ST   D6S1043: 13,21
ST   D7S820: 9,11
ST   D8S1179: 13,16
ST   FGA: 19.2,25
ST   Penta D: 6,10
ST   Penta E: 10,16
ST   TH01: 7,8 (CLS; ECACC; JCRB; KCLB; PubMed=25877200; PubMed=31378681)
ST   TH01: 8 (ATCC; CCRID)
ST   TPOX: 8
ST   vWA: 15,16
DI   NCIt; C7956; Adult hepatocellular carcinoma
DI   ORDO; Orphanet_210159; Adult hepatocellular carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   24Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 43
RX   DOI=10.1007/978-4-431-68349-0_4;
RA   Alexander J.J.;
RT   "Human hepatoma cell lines.";
RL   (In) Neoplasms of the liver; Okuda K., Ishak K.G. (eds.); pp.47-56; Springer; Tokyo (1987).
RX   DOI=10.11418/jtca1981.16.3_173;
RA   Mihara K., Miyazaki M., Fushimi K., Tsuji T., Inoue Y., Fukaya K.-i.,
RA   Ohashi R., Namba M.;
RT   "The p53 gene status and other cellular characteristics of human cell
RT   lines maintained in our laboratory.";
RL   Tissue Cult. Res. Commun. 16:173-178(1997).
RX   PubMed=63998;
RA   Alexander J.J., Bey E.M., Geddes E.W., Lecatsas G.;
RT   "Establishment of a continuously growing cell line from primary
RT   carcinoma of the liver.";
RL   S. Afr. Med. J. 50:2124-2128(1976).
RX   PubMed=184551;
RA   Alexander J.J., Bey E.M., Whitcutt J.M., Gear J.H.S.;
RT   "Adaptation of cells derived from human malignant tumours to growth in
RT   vitro.";
RL   S. Afr. J. Med. Sci. 41:89-98(1976).
RX   PubMed=187208; DOI=10.1038/bjc.1976.205;
RA   MacNab G.M., Alexander J.J., Lecatsas G., Bey E.M., Urbanowicz J.M.;
RT   "Hepatitis B surface antigen produced by a human hepatoma cell line.";
RL   Br. J. Cancer 34:509-515(1976).
RX   PubMed=1317878; DOI=10.1016/0166-0934(92)90047-h;
RA   Grabow W.O.K., Puttergill D.L., Bosch A.;
RT   "Propagation of adenovirus types 40 and 41 in the PLC/PRF/5 primary
RT   liver carcinoma cell line.";
RL   J. Virol. Methods 37:201-207(1992).
RX   PubMed=1661347; DOI=10.2302/kjm.40.139;
RA   Saito H., Morizane T., Watanabe T., Kagawa T., Miyaguchi S.,
RA   Kumagai N., Tsuchimoto K., Tsuchiya M.;
RT   "Proto-oncogene expression in three human hepatoma cell lines, HCC-M,
RT   HCC-T and PLC/PRF/5.";
RL   Keio J. Med. 40:139-145(1991).
RX   PubMed=2414854;
RA   Aspinall S., Alexander J.J.;
RT   "Hepatitis B virus gene expression in two cell lines, one derived from
RT   a natural human infection, the other experimentally infected in
RT   vitro.";
RL   S. Afr. Med. J. 68:751-754(1985).
RX   PubMed=2439335; DOI=10.1111/j.1432-1033.1987.tb11497.x;
RA   Vincent C., Marceau M., Blangarin P., Bouic P., Madjar J.-J.,
RA   Revillard J.-P.;
RT   "Purification of alpha 1-microglobulin produced by human hepatoma cell
RT   lines. Biochemical characterization and comparison with alpha
RT   1-microglobulin synthesized by human hepatocytes.";
RL   Eur. J. Biochem. 165:699-704(1987).
RX   PubMed=2542205; DOI=10.1111/j.1349-7006.1989.tb02290.x;
RA   Tsuda H., Hirohashi S., Shimosato Y., Ino Y., Yoshida T., Terada M.;
RT   "Low incidence of point mutation of c-Ki-ras and N-ras oncogenes in
RT   human hepatocellular carcinoma.";
RL   Jpn. J. Cancer Res. 80:196-199(1989).
RX   PubMed=2992761; DOI=10.1016/0165-4608(85)90033-0;
RA   Pinto M.R., Bey E., Bernstein R.;
RT   "The PLC/PRF/5 human hepatoma cell line. I. Reevaluation of the
RT   karyotype.";
RL   Cancer Genet. Cytogenet. 18:11-18(1985).
RX   PubMed=2992762; DOI=10.1016/0165-4608(85)90034-2;
RA   Bowcock A.M., Pinto M.R., Bey E., Kuyl J.M., Dusheiko G.M.,
RA   Bernstein R.;
RT   "The PLC/PRF/5 human hepatoma cell line. II. Chromosomal assignment of
RT   hepatitis B virus integration sites.";
RL   Cancer Genet. Cytogenet. 18:19-26(1985).
RX   PubMed=3023526; DOI=10.1099/0022-1317-67-11-2315;
RA   Aspinall S., Alexander J.J., Bos P.;
RT   "Comparative expression of hepatitis B virus antigens in several cell
RT   model systems.";
RL   J. Gen. Virol. 67:2315-2323(1986).
RX   PubMed=6160110; DOI=10.1128/IAI.30.2.607-611.1980;
RA   Daemer R.J., Feinstone S.M., Alexander J.J., Tully J.G., London W.T.,
RA   Wong D.C., Purcell R.H.;
RT   "PLC/PRF/5 (Alexander) hepatoma cell line: further characterization
RT   and studies of infectivity.";
RL   Infect. Immun. 30:607-611(1980).
RX   PubMed=6225510; DOI=10.1007/BF00199161;
RA   Keong A., Rabson A.R.;
RT   "Supernatant derived from a human hepatocellular carcinoma cell line
RT   (PLC/PRF/5) activates a population of T-suppressor cells.";
RL   Cancer Immunol. Immunother. 15:178-182(1983).
RX   PubMed=6248960; DOI=10.1126/science.6248960;
RA   Knowles B.B., Howe C.C., Aden D.P.;
RT   "Human hepatocellular carcinoma cell lines secrete the major plasma
RT   proteins and hepatitis B surface antigen.";
RL   Science 209:497-499(1980).
RX   PubMed=6268737; DOI=10.1099/0022-1317-53-1-105;
RA   Oefinger P.E., Bronson D.L., Dreesman G.R.;
RT   "Induction of hepatitis B surface antigen in human hepatoma-derived
RT   cell lines.";
RL   J. Gen. Virol. 53:105-113(1981).
RX   PubMed=6275024; DOI=10.1099/0022-1317-57-1-95;
RA   Koshy R., Maupas P., Muller R., Hofschneider P.H.;
RT   "Detection of hepatitis B virus-specific DNA in the genomes of human
RT   hepatocellular carcinoma and liver cirrhosis tissues.";
RL   J. Gen. Virol. 57:95-102(1981).
RX   PubMed=6288577; DOI=10.1002/ijc.2910300106;
RA   Simon D., Aden D.P., Knowles B.B.;
RT   "Chromosomes of human hepatoma cell lines.";
RL   Int. J. Cancer 30:27-33(1982).
RX   PubMed=6555060; DOI=10.1007/BF00199162;
RA   Keong A., Herman J., Rabson A.R.;
RT   "Supernatant derived from a human hepatocellular carcinoma cell line
RT   (PLC/PRF/5) depresses natural killer (NK) cell activity.";
RL   Cancer Immunol. Immunother. 15:183-187(1983).
RX   PubMed=6889516; DOI=10.1016/0277-5379(82)90010-4;
RA   Sattler F.R., Paolucci S., Kreider J.W., Ladda R.L.;
RT   "A human hepatoma cell line (PCL/PRF/5) produces lung metastases and
RT   secretes HBsAg in nude mice.";
RL   Eur. J. Cancer Clin. Oncol. 18:381-389(1982).
RX   PubMed=7874267; DOI=10.1007/BF02349278;
RA   Ikuta S., Itoh F., Hinoda Y., Toyota M., Makiguchi Y., Imai K.,
RA   Yachi A.;
RT   "Expression of cytoskeletal-associated protein tyrosine phosphatase
RT   PTPH1 mRNA in human hepatocellular carcinoma.";
RL   J. Gastroenterol. 29:727-732(1994).
RX   PubMed=8050184; DOI=10.1111/j.1365-2249.1994.tb06089.x;
RA   Wadee A.A., Paterson A., Coplan K.A., Reddy S.G.;
RT   "HLA expression in hepatocellular carcinoma cell lines.";
RL   Clin. Exp. Immunol. 97:328-333(1994).
RX   PubMed=8224613; DOI=10.1096/fasebj.7.14.8224613;
RA   Puisieux A., Galvin K., Troalen F., Bressac B., Marcais C., Galun E.,
RA   Ponchel F., Yakicier C., Ji J.-W., Ozturk M.;
RT   "Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell
RT   lines.";
RL   FASEB J. 7:1407-1413(1993).
RX   PubMed=8389256; DOI=10.1093/carcin/14.5.987;
RA   Hsu I.C., Tokiwa T., Bennett W., Metcalf R.A., Welsh J.A., Sun T.,
RA   Harris C.C.;
RT   "p53 gene mutation and integrated hepatitis B viral DNA sequences in
RT   human liver cancer cell lines.";
RL   Carcinogenesis 14:987-992(1993).
RX   PubMed=8835345; DOI=10.1002/(SICI)1096-9071(199602)48:2<133::AID-JMV3>3.0.CO;2-A;
RA   Tsuboi S., Nagamori S., Miyazaki M., Mihara K., Fukaya K.-i., Teruya K.,
RA   Kosaka T., Tsuji T., Namba M.;
RT   "Persistence of hepatitis C virus RNA in established human
RT   hepatocellular carcinoma cell lines.";
RL   J. Med. Virol. 48:133-140(1996).
RX   PubMed=9023415; DOI=10.1006/cimm.1996.1062;
RA   Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.;
RT   "HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating
RT   lymphocytes of patients with non-small cell lung cancer.";
RL   Cell. Immunol. 175:101-110(1997).
RX   PubMed=9178645; DOI=10.1006/cimm.1997.1108;
RA   Nakao M., Sata M., Saitsu H., Yutani S., Kawamoto M., Kojiro M.,
RA   Itoh K.;
RT   "CD4+ hepatic cancer-specific cytotoxic T lymphocytes in patients with
RT   hepatocellular carcinoma.";
RL   Cell. Immunol. 177:176-181(1997).
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
RX   PubMed=9359923; DOI=10.18926/AMO/30789;
RA   Mihara K., Miyazaki M., Kondo T., Fushimi K., Tsuji T., Inoue Y.,
RA   Fukaya K.-i., Ishioka C., Namba M.;
RT   "Yeast functional assay of the p53 gene status in human cell lines
RT   maintained in our laboratory.";
RL   Acta Med. Okayama 51:261-265(1997).
RX   PubMed=10523694; DOI=10.3892/or.6.6.1267;
RA   Gao C., Ohashi R., Pu H., Inoue Y., Tsuji T., Miyazaki M., Namba M.;
RT   "Yeast functional assay of the p53 gene status in 11 cell lines and 26
RT   surgical specimens of human hepatocellular carcinoma.";
RL   Oncol. Rep. 6:1267-1271(1999).
RX   PubMed=11050057; DOI=10.1053/jhep.2000.19349;
RA   Wong N., Lai P., Pang E., Leung T.W.-T., Lau J.W.-L., Johnson P.J.;
RT   "A comprehensive karyotypic study on human hepatocellular carcinoma by
RT   spectral karyotyping.";
RL   Hepatology 32:1060-1068(2000).
RX   PubMed=12029633; DOI=10.1053/jhep.2002.33683;
RA   Yasui K., Arii S., Zhao C., Imoto I., Ueda M., Nagai H., Emi M.,
RA   Inazawa J.;
RT   "TFDP1, CUL4A, and CDC16 identified as targets for amplification at
RT   13q34 in hepatocellular carcinomas.";
RL   Hepatology 35:1476-1484(2002).
RX   PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234;
RA   Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y.,
RA   Yamori T.;
RT   "Chemosensitivity profile of cancer cell lines and identification of
RT   genes determining chemosensitivity by an integrated bioinformatical
RT   approach using cDNA arrays.";
RL   Mol. Cancer Ther. 4:399-412(2005).
RX   PubMed=20069059; DOI=10.1155/2010/437143;
RA   Srisomsap C., Sawangareetrakul P., Subhasitanont P.,
RA   Chokchaichamnankit D., Chiablaem K., Bhudhisawasdi V., Wongkham S.,
RA   Svasti J.;
RT   "Proteomic studies of cholangiocarcinoma and hepatocellular carcinoma
RT   cell secretomes.";
RL   J. Biomed. Biotechnol. 2010:437143.1-437143.18(2010).
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
RX   PubMed=23505090; DOI=10.1002/hep.26402;
RA   Wang K., Lim H.Y., Shi S., Lee J., Deng S.-B., Xie T., Zhu Z.,
RA   Wang Y.-L., Pocalyko D., Yang W.J., Rejto P.A., Mao M., Park C.-K.,
RA   Xu J.-C.;
RT   "Genomic landscape of copy number aberrations enables the
RT   identification of oncogenic drivers in hepatocellular carcinoma.";
RL   Hepatology 58:706-717(2013).
RX   PubMed=23887712; DOI=10.1038/ncomms3218;
RA   Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P.,
RA   Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.;
RT   "High frequency of telomerase reverse-transcriptase promoter somatic
RT   mutations in hepatocellular carcinoma and preneoplastic lesions.";
RL   Nat. Commun. 4:2218.1-2218.7(2013).
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
RX   PubMed=25574106; DOI=10.3748/wjg.v21.i1.311;
RA   Cevik D., Yildiz G., Ozturk M.;
RT   "Common telomerase reverse transcriptase promoter mutations in
RT   hepatocellular carcinomas from different geographical locations.";
RL   World J. Gastroenterol. 21:311-317(2015).
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
RX   PubMed=29892436; DOI=10.1098/rsos.172472;
RA   Shioda S., Kasai F., Watanabe K., Kawakami K., Ohtani A., Iemura M.,
RA   Ozawa M., Arakawa A., Hirayama N., Kawaguchi E., Tano T., Miyata S.,
RA   Satoh M., Shimizu N., Kohara A.;
RT   "Screening for 15 pathogenic viruses in human cell lines registered at
RT   the JCRB Cell Bank: characterization of in vitro human cells by viral
RT   infection.";
RL   R. Soc. Open Sci. 5:172472-172472(2018).
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
RX   PubMed=31063779; DOI=10.1053/j.gastro.2019.05.001;
RA   Caruso S., Calatayud A.-L., Pilet J., La Bella T., Rekik S.,
RA   Imbeaud S., Letouze E., Meunier L., Bayard Q., Rohr-Udilova N.,
RA   Peneau C., Grasl-Kraupp B., de Koning L., Ouine B., Bioulac-Sage P.,
RA   Couchy G., Calderaro J., Nault J.-C., Zucman-Rossi J., Rebouissou S.;
RT   "Analysis of liver cancer cell lines identifies agents with likely
RT   efficacy against hepatocellular carcinoma and markers of response.";
RL   Gastroenterology 157:760-776(2019).
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
RX   PubMed=31378681; DOI=10.1016/j.ccell.2019.07.001;
RA   Qiu Z.-X., Li H., Zhang Z.-T., Zhu Z.-F., He S., Wang X.-J.,
RA   Wang P.-C., Qin J.-J., Zhuang L.-P., Wang W., Xie F.-B., Gu Y.,
RA   Zou K.-K., Li C., Li C., Wang C.-H., Cen J., Chen X.-T., Shu Y.-J.,
RA   Zhang Z., Sun L.-L., Min L.-H., Fu Y., Huang X.-W., Lv H., Zhou H.,
RA   Ji Y., Zhang Z.-G., Meng Z.-Q., Shi X.-L., Zhang H.-B., Li Y.-X.,
RA   Hui L.-J.;
RT   "A pharmacogenomic landscape in human liver cancers.";
RL   Cancer Cell 36:179-193.e11(2019).